Clinical Trial Update: Fludara (Oral) Phase II Study for Indolent Lymphoma [Phase 2]

View source ↗

Summary

A Phase II trial of oral fludarabine for indolent non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Fludara (fludarabine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Lymphoma | Phase 2 | Status: COMPLETED